HUMAN LUNG SURFACTANT DEFICIENCY DIAGNOSIS AND THERAPY

人肺表面活性剂缺乏症的诊断和治疗

• 批准号: 3499258
• 负责人: BARBARA L CORDELL
• 金额: $ 5万
• 依托单位: CALIFORNIA BIOTECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-04-01 至 1985-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3499258
• 关键词: adult respiratory distress syndrome; biotechnology; enzyme linked immunosorbent assay; genetic manipulation; human tissue; immunologic assay /test; molecular cloning; molecular genetics; monoclonal antibody; pulmonary surfactants; respiratory disorder chemotherapy; respiratory disorder diagnosis; respiratory distress syndrome of newborn; tissue /cell culture

This proposal describes the development of a modern diagnostic test and therapy for infant respiratory distress syndrome (RDS). RDS is the leading cause of neonate mortality and morbidity. It is due to inadequate levels of lung surfactant, a lipid-protein complex essential for lung inflation. Current diagnostic assays are based on the lipid component of surfactant and are unreliable. We propose to develop a sensitive and accurate enzyme-linked immunoadsorbant assay directed against the major protein component of surfactant. RDS is now treated with a respirator until surfactant develops, yet this often leads to lung disorders. Natural surfactant has been successfully administered as a therapy but limited availablity makes this approach impracticable for routine therapy. Recombinant DNA technology will be used to produce the needed surfactant protein. The human gene encoding the protein will be cloned and expressed, and the approtein constituted with lipids to provide a safe and effective therapy.

该提案描述了现代诊断测试的发展， 治疗婴儿呼吸窘迫综合征（RDS）。 RDS是领先的 新生儿死亡和发病的原因。 这是由于水平不足， 肺表面活性剂，一种对肺部充气至关重要的脂质-蛋白质复合物。 目前的诊断分析是基于表面活性剂的脂质成分 并且不可靠。 我们建议制定一个敏感和准确的 针对主要蛋白质的酶联免疫吸附测定 表面活性剂组分。 呼吸窘迫综合征现在用呼吸器治疗， 表面活性剂的发展，但这往往导致肺部疾病。 自然 表面活性剂已成功用作治疗方法，但效果有限 可用性使得该方法对于常规治疗是不可行的。 重组DNA技术将用于生产所需的表面活性剂 蛋白 编码该蛋白的人类基因将被克隆和表达， 以及由脂质构成的Aptein，以提供安全有效的 疗法

项目成果

Monoclonal antibodies to surfactant proteins SP28-36 label canine type II and nonciliated bronchiolar cells by immunofluorescence.

表面活性剂蛋白 SP28-36 的单克隆抗体通过免疫荧光标记犬 II 型和非纤毛细支气管细胞。

• DOI: 10.1164/ajrccm/137.2.399
• 发表时间: 1988
• 期刊: The American review of respiratory disease
• 作者: Williams,MC;Hawgood,S;Schenk,DB;Lewicki,J;Phelps,MN;Benson,B
• 通讯作者: Benson,B